✦ LIBER ✦

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

✍ Scribed by Terri M. Wensel; Maryam M. Iranikhah; Teresa W. Wilborn

Book ID: 115050229
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 249 KB
Volume: 31
Category: Article
ISSN: 0277-0008
DOI: 10.1592/phco.31.5.510

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of denosumab on bone mineral den

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

✍ David L Kendler; Christian Roux; Claude Laurent Benhamou; Jacques P Brown; Micha 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 146 KB

Denosumab in postmenopausal women with l

Denosumab in postmenopausal women with low bone mineral density

✍ Charles L. Loprinzi 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 51 KB

Dose–response study of denosumab on bone

Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis

✍ T. Nakamura; T. Matsumoto; T. Sugimoto; M. Shiraki 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 500 KB

The effects ofAcanthopanax senticosusext

The effects ofAcanthopanax senticosusextract on bone turnover and bone mineral density in Korean postmenopausal women

✍ You-Cheol Hwang; In-Kyung Jeong; Kyu Jeung Ahn; Ho Yeon Chung 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 187 KB

Bone turnover markers and bone mineral d

Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment

✍ José M. Olmos; José L. Hernández; Josefina Martínez; Jesús Castillo; Carmen Vale 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Effects of denosumab on bone turnover ma

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat